A conserved glucagon signaling pathway links high-fat diet-induced metabolic imbalance to cardiac arrhythmia through hormone-producing cells and heart-innervating neurons that regulate rhythmicity.

Add Yahoo as a preferred source to see more of our stories on Google. The trial aims to address the weight loss plateau with semaglutide by adding enobosarm to preserve muscle and function. Credit: ...

The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients ...

New research reveals GLP-1 weight-loss drugs may boost or decrease sexual function, with 52% of users reporting changes in ...

Understood reports GLP-1 drugs like Ozempic may improve ADHD symptoms by quieting food thoughts, but more research is needed for direct effects.

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

The human body runs on chemistry—from the water that regulates temperature to the proteins that carry oxygen and signal cells ...

As overweight and obesity levels rise in populations the world over, they pose much more than cosmetic and mobility challenges to people. Body fat, especially v ...

Certain foods can naturally reduce appetite and slow down gastric emptying by stimulating the release of GLP-1 and other satiety hormones.

Tracking over 600,000 veterans shows that GLP-1 receptor agonists are linked to lower rates of substance use disorders, fewer overdoses, and fewer addiction-related hospital visits.

Glucagon-like peptide-1 (GLP-1) is a hormone secreted after eating to stimulate insulin release and suppress glucagon, a hormone that raises blood sugar, helping to lower blood sugar.

China approves Pfizer’s GLP-1 weight-loss drug, expanding competition in the booming obesity treatment market and highlighting rising metabolic health concerns.